DBS of the SCC for the Treatment of Medically Refractory CLBP
NCT04085406
Recruiting
The purpose of this study is to evaluate the feasibility and preliminary efficacy of deep brain stimulation of the subgenual cingulate cortex for the treatment of chronic medically-refractory low back pain using a randomized double-blind crossover design.
Gender:
ALL
Ages:
Between 40 years and 75 years
Trial Updated:
02/14/2025
Locations: University of California Los Angeles, Los Angeles, California +1 locations
Conditions: Chronic Low-back Pain
Register for Updates
Post Marketing Study of MagnetOs Easypack Putty Standalone Compared to Demineralized Bone Matrix or Fibers Mixed with Autograft in Patients Undergoing Posterolateral Lumbar Fusion
NCT04679844
Recruiting
This is a phase IV post-marketing study for MagnetOs Easypack Putty. MagnetOs Easypack Putty is a synthetic bone graft extender product that is routinely used by surgeons as a treatment for patients with degenerative disc disease or spinal trauma undergoing spinal fusion surgery. In this study, MagnetOs Easypack Putty will be used according to the latest U.S. Instructions For Use, standalone in the posterolateral spine.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/14/2025
Locations: Tennessee Orthopaedic Alliance, Nashville, Tennessee +1 locations
Conditions: Degenerative Disc Disease, Spine Fusion, Back Pain
Register for Updates
A Feasibility Trial to Investigate the Safety and Between-group Effect Size of STIMULAN VG and Standard of Care (SoC) in Participants With Diabetic Foot Osteomyelitis
NCT05539963
Recruiting
The purpose of this trial is to evaluate the safety and between-group effect size of STIMULAN VG compared to SoC treatment in patients with diabetic foot osteomyelitis (DFO).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/14/2025
Locations: Titan Clinical Research, Mesa, Arizona +7 locations
Conditions: Diabetic Foot Osteomyelitis
Register for Updates
Family-Based Treatment for Type 1 Diabetes
NCT05756361
Recruiting
Type 1 Diabetes carries high burden for affected youth and their families. Advances in insulin therapy and technology have been associated with increased obesity with 1/3 adolescents being overweight/obese. Since obesity runs in families and carries risk for poor outcomes psychologically and medically, the investigators are adapting our successful evidence-based Family Based Treatment for hybrid delivery to improve obesity and metabolic control in the affected youth and improve obesity and relat... Read More
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
02/14/2025
Locations: Conventus, Buffalo, New York
Conditions: Diabetes Mellitus, Type 1, Obesity, Childhood, Overweight, Comorbidities and Coexisting Conditions
Register for Updates
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
NCT06031688
Recruiting
This phase II Expanded Lung-MAP treatment trial tests tepotinib with or without ramucirumab for the treatment of patients with advanced non-small cell lung cancer that has spread from where it first started (primary site) to other places in the body (stage IV) or that has come back after a period of improvement (recurrent). Tepotinib is used in patients whose cancer has a mutated (changed) form of a gene called MET. It is in a class of medications called kinase inhibitors. It works by blocking t... Read More
Gender:
ALL
Ages:
All
Trial Updated:
02/14/2025
Locations: NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro, Jonesboro, Arkansas +239 locations
Conditions: Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Register for Updates
BostonGene and Exigent Genomic INsight Study
NCT06272864
Recruiting
The BEGIN Study by BostonGene and Exigent Genomic INsight evaluates the efficacy of comprehensive molecular testing in advanced cancer patients. Using the BostonGene Tumor Portrait test, the study aims to identify actionable findings, assess feasibility, and determine patient enrollment in clinical trials. Four cohorts of 100 patients each will be studied over two years, focusing on treatment decisions and patient outcomes. This study seeks to demonstrate the clinical utility of genomic testing... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/14/2025
Locations: Highlands Oncology Group, Rogers, Arkansas +6 locations
Conditions: Breast Cancer, Non-small Cell Lung Cancer, Melanoma, Sarcoma
Register for Updates
Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia
NCT06549790
Recruiting
The aim of PERKA-812-003 study is to investigate the safety, pharmacokinetics and preliminary anti-tumor activity of treatment with NMS-03597812 as single agent in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) patients who have exhausted standard treatment, including a subset of patients with TP53 mutations. It is anticipated that combination with venetoclax will be further evaluated following a future protocol amendment, once the Recommended Range Dose (RDR) as single agent has been defi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/14/2025
Locations: City of Hope - Duarte, Duarte, California +5 locations
Conditions: Relapsed/Refractory Acute Myeloid Leukemia
Register for Updates
Exploring Neurophysiological Markers of Brain Health
NCT06731452
Recruiting
The combination of transcranial magnetic stimulation (TMS) and electroencephalography (EEG) has been suggested as a promising brain imaging tool for identifying biomarkers of brain health. In this pilot study, study investigators will explore the neurophysiological metrics of brain health with a non-invasive brain imaging technique, alongside behavioral and fMRI metrics collected through another study (NCT04869111).
Gender:
ALL
Ages:
Between 22 years and 100 years
Trial Updated:
02/14/2025
Locations: Center for BrainHealth at The University of Texas at Dallas, Dallas, Texas
Conditions: Healthy Lifestyle, Health-Related Behavior
Register for Updates
The LD Lync Study - Natural History Study of Lipodystrophy Syndromes
NCT03087253
Recruiting
Genetic lipodystrophy syndromes are extremely rare, orphan diseases with overall estimated prevalence of less than 2,000 in the United States. These rare disorders characterized by selective loss of adipose tissue and predisposition to insulin resistance and its metabolic complications diabetes, dyslipidemia and hepatic steatosis. Due to these metabolic problems, atherosclerotic vascular disease, recurrent episodes of acute pancreatitis, cirrhosis and other morbidities complicate the lives of th... Read More
Gender:
ALL
Ages:
All
Trial Updated:
02/14/2025
Locations: National Institutes of Health, Bethesda, Maryland +2 locations
Conditions: Lipodystrophy (Genetic or Acquired, Non HIV)
Register for Updates
Study of CTDNA Response Adaptive Immuno-Chemotherapy in NSCLC
NCT04093167
Recruiting
BR36 will evaluate the potential clinical benefit of tailoring immunotherapy treatment based on ctDNA molecular response in non-small cell lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/14/2025
Locations: The Sidney Kimmel Comprehensive Cancer Centre, Baltimore, Maryland +5 locations
Conditions: Non-Small Cell Lung Cancer
Register for Updates
Fluorescent Intra-operative Tumor Margin Examination
NCT04719156
Recruiting
Tumor margin confirmation is important to confirming appropriate disease excision. Current standard of care is to take select margin samples to pathology for intra-operative readings. However, this is expensive, time consuming, and only assesses the margin contained within the specific sample. In prior work the investigators have determined that indocyanine green (ICG) is highly specific to the tumor bed when injected shortly before surgery. The investigators hypothesize that ICG will be able to... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
02/14/2025
Locations: UPMC-Shadyside Hospital, Pittsburgh, Pennsylvania
Conditions: Sarcoma
Register for Updates
Study of Oral MRT-2359 in Selected Cancer Patients
NCT05546268
Recruiting
This Phase 1/2, open-label, multicenter study is conducted in patients with previously treated selected solid tumors, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), high-grade neuroendocrine cancer of any primary site, diffuse large B-cell lymphoma (DLBCL), and tumors with L-MYC or N-MYC amplification. Patients receive escalating doses of a GSPT1 molecular glue degrader MRT-2359 to determine safety, tolerability, maximum tolerated dose (MTD) and/or recommended Phase... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/14/2025
Locations: Honor Health Research Institute, Scottsdale, Arizona +19 locations
Conditions: NSCLC, SCLC, DLBCL, NSCLC With High or Low L-MYC or N-MYC Expression, High Grade Neuroendocrine Cancer, L-MYC and N-MYC Amplified Solid Tumors, HR-positive, HER2-negative Breast Cancer, Prostate Cancer
Register for Updates